Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus C Elze

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 8, 2018
Phase II, Open-Label, Randomized, Multicenter Trial (HERBY) of Bevacizumab in Pediatric Patients With Newly Diagnosed High-Grade GliomaJacques Grill, Maura Massimino, Eric Bouffet, et al.
International Journal of Radiation Oncology, Biology, Physics|July 4, 2021
The Impact of Radiation Therapy in Children and Adolescents With Metastatic RhabdomyosarcomaAlison L Cameron, Markus C Elze, Michela Casanova, et al.
Nature Communications|May 15, 2024
CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trialsNeil H Segal, Ignacio Melero, Victor Moreno, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 8, 2018
Phase II, Open-Label, Randomized, Multicenter Trial (HERBY) of Bevacizumab in Pediatric Patients With Newly Diagnosed High-Grade GliomaJacques Grill, Maura Massimino, Eric Bouffet, et al.
International Journal of Radiation Oncology, Biology, Physics|July 4, 2021
The Impact of Radiation Therapy in Children and Adolescents With Metastatic RhabdomyosarcomaAlison L Cameron, Markus C Elze, Michela Casanova, et al.
Nature Communications|May 15, 2024
CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trialsNeil H Segal, Ignacio Melero, Victor Moreno, et al.
Pageof 2